Versartis growth hormone drug fails key study, shares sink
September 21, 2017 at 17:59 PM EDT
Sept 21 (Reuters) - Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.